Zero Candida Technologies Inc.
TTSXV:ZCT0.11
CAD
0.00
(0.00%)
ISIN
CA9894831028
CUSIP
989483102
Return %
Stock
S&P 500
1Y
-60.00
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Eli Ben-Haroosh
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Vancouver Canada
- IPO Date
- Nov 25, 2024
- Website
- zero-candida.com
- Similar Companies
- Business
- Zero Candida Technologies Inc. is a clinical-stage medical technology and biotechnology company that specializes in the research, development, and commercialization of non-pharmacological, light-based therapeutic solutions for the treatment and prevention of fungal infections. The company operates within the healthcare and medical device sectors, focusing on non-invasive phototherapy treatments for vulvovaginal candidiasis and recurrent fungal conditions. Its core product and service offerings include non-invasive antimicrobial phototherapy medical devices; prescription and over-the-counter home-use therapeutic applicators designed to target Candida albicans and drug-resistant fungal strains without inducing antimicrobial resistance; clinical-grade treatment systems for gynecological practices and specialized healthcare facilities; disposable optical diffusers, sterile protective sheaths, and related single-use accessories; digital health companion applications for treatment schedule management and clinical outcome tracking; and preclinical and clinical research services for phototherapeutic protocol development. The company caters to women's health clinics, obstetricians, gynecologists, hospitals, and direct-to-consumer health markets across North America and international territories. In recent corporate developments, the company completed a qualifying transaction and corporate reorganization resulting in its formal name change to Zero Candida Technologies Inc. and the listing of its common shares on the TSX Venture Exchange under the symbol ZCT. Additionally, the company closed private placement equity financings to fund ongoing clinical validation studies, expanded its global intellectual property portfolio with granted patents and patent applications for proprietary wavelength emission mechanisms, and formed strategic partnerships with contract development and manufacturing organizations (CDMOs) and clinical research organizations (CROs) to support regulatory clearance initiatives with Health Canada and the United States Food and Drug Administration. Zero Candida Technologies Inc. was founded in 2021 and is headquartered in Vancouver, British Columbia, Canada.